公司演示-康宁杰瑞

English 中文简体中文繁体

English 中文简体中文繁体

投资者关系

信息披露

公司治理

股票信息

投资者查询

电邮订阅

公司演示

康宁杰瑞生物制药投资人演示材料 2021-08-30
公司演示材料更新 2021-05-12
AACR poster #1660_KN046(PD-L1/CTLA-4双特异性抗体)联合白蛋白结合型紫杉醇治疗转移性三阴乳腺癌患者的初步安全性、耐受性和疗效结果 2021-04-12
2020年度业绩投资人演示材料 2021-03-24
2020世界肺癌大会壁报-KN046用于治疗晚期非小细胞肺癌(NSCLC)患者的Ⅱ期临床研究数据 2021-02-01
2020世界肺癌大会迷你口头报告-KN046在罕见胸部肿瘤患者中的初步安全性和有效性结果 2021-02-01
公司演示材料更新 2021-01-21
ASCO-GI poster-KN046联合放化疗治疗复发和转移性食管鳞癌的初步疗效和安全性数据 2021-01-18
2020 Jefferies伦敦线上医疗投资峰会演示材料 2020-11-16
SITC 壁报-KN026与KN046联合治疗HER2阳性实体瘤患者的安全性、耐受性和抗肿瘤活性初步结果 2020-11-12
第27届CITIC CLSA年度投资峰会演示材料 2020-09-22
2020 Interim Result Investor Presentation 2020-08-28
Company recent development report - July 2020 2020-07-30
AACR poster #1181 - Using translational tumor growth inhibition modeling approach and population PK analysis to predict efficacious doses for KN026, a HER2 bispecific antibody 2020-06-22
2020 Jefferies Virtual Healthcare Conference 2020-06-02
ASCO poster #3021 - Envafolimab (KN035) in advanced tumors with mismatch-repair deficiency 2020-05-29
ASCO poster #1041 - Preliminary Safety, Efficacy and Pharmacokinetics (PK) Results of KN026, a HER2-targeted Bispecific Antibody in Patients (pts) with HER2-positive Metastatic Breast Cancer 2020-05-29
ASCO poster #3020 - The preliminary efficacy and safety data of KN046 (bispecific anti-PD-L1/CTLA4) in patients failed on prior immune checkpoint inhibitors therapy 2020-05-29
Using translational tumor growth inhibition modeling approach and population PK analysis to predict efficacious doses for KN026, a HER2 bispecific antibody 2020-05-28
Envafolimab (KN035) in advanced tumors with mismatch-repair deficiency 2020-05-28
The preliminary efficacy and safety data of KN046 in patients failed on prior immune checkpoint inhibitors therapy 2020-05-17
Preliminary safety, efficacy and pharmacokinetics (PK) results of KN026, a HER2 bispecific antibody in patients (pts) with HER2-positive metastatic breast cancer 2020-05-17